Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Synchrony Financial (SYF) vs GeneDx Holdings Corp (WGS) Price & Performance

Synchrony FinancialTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Synchrony Financial vs GeneDx Holdings Corp — how do they compare? Synchrony Financial trades at $78.37 (market cap $25.53B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Synchrony Financial is far larger — about 10.5× GeneDx Holdings Corp's market cap, and Synchrony Financial pays a 1.73% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

SYFWGS
Market Cap
$25.53B$2.44B
Sector
FinancialsTechnology
52-Week High
$88.47$167.51
52-Week Low
$63.78$34.51
Dividend Yield
1.73%
Enterprise Value
$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Synchrony Financial

Synchrony Financial (SYF) trades at $79.41, up 1.56% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed $2.59 EPS, beating estimates by 24.5%, while the CareCredit partnership with Stripe expands financing access for health providers.

SYF presents attractive value with robust capital returns including aggressive buybacks and dividends. Analyst consensus is strongly bullish with a $86.33 price target representing 8.7% upside. Key risks include consumer credit deterioration and rising expenses, but stable purchase volume growth and improved net interest margin outlook support continued earnings growth potential.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS